DXA detected a significant decline in BMD at cortical sites, whereas REMS did not, and the correlation of the annualized changes between the two methods in assessing changes over time was poor. Given the small sample size, larger studies are needed to clarify the comparative and possible complementary roles of REMS and DXA in monitoring bone health in end-stage kidney disease.
Lopes et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: